Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Differential mRNA expression analysis of H358 and AsPC-1 cell xenograft mouse model after MCB-22-294 treatment

ABSTRACT: The mechanism of action of a pan-Kras inhibitor MCB-22-294 remains unknown. We determined gene expression profiling in H358 and AsPC-1 cell line xenograft mouse models after MCB-22-294 treatment using RNA-seq analysis.

ORGANISM(S): Homo sapiens

PROVIDER: GSE249914 | GEO | 2024/02/22

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Differential mRNA expression analysis of H358 and AsPC-1 cell xenograft mouse model after MCB-22-294 treatment

Project description:Differential mRNA expression analysis of H358 and AsPC-1 cell xenograft mouse model after MCB-22-294 treatment

| PRJNA1051129 | ENA

Label-free quantitative proteomics analysis of ASPC-1 and H358

Project description:ASPC-1 and H358 cells were collected after being treated with 100nM MCB-36 for 24h. Cells were lysed in UA solution followed by mechanical grinding at a frequency of 60 Hz at 4°C for 60 min. The lysate was centrifuged and the supernatant was collected as a whole extract. Samples were then digested using the filter-aided sample preparation method. Liquid chromatography tandem MS (LC-MS/MS) analysis was performed by coupling a nanoLC column to an Orbitrap Q-Exactive Plus mass spectrometer.

2023-11-30 | PXD047389 |

A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers [CD45+ scRNA-seq]

Project description:KRAS is the most frequently mutated oncogene in human cancers, but to date, only KRASG12C inhibitors have been FDA-approved. Small-molecule inhibitors that target other more prevalent KRAS mutations are in urgent clinical need. Here, we report a highly potent pan-KRAS inhibitor, MCB-294, that selectively targets KRAS, but not HRAS or NRAS. Molecular profiling studies show that MCB-294 binds to and inhibits several KRAS mutants, including G12D, G12C, G12V, thereby disabling KRAS oncogenic signaling. MCB-294 is well tolerated in mice and exhibits remarkable therapeutic efficacy against the growth of a comprehensive range of KRAS-driven cancer cell lines, patient-derived organoids, and tumor xenografts and prolongs mouse survival. By employing an MCB-294 derivative as the KRAS binder, we further identify a VHL-based pan-KRAS degrader, MCB-36, that efficiently degrades KRAS in vitro and in vivo through the ubiquitin-proteasome system. Importantly, MCB-294 and MCB-36 not only effectively kill KRASG12C inhibitor-resistant cells, but also reshape the tumor microenvironment by boosting T cell-mediated anti-tumor immunity. Taken together, our findings demonstrate a successful and feasible strategy for targeting pan-KRAS to impair multifaceted features of KRAS-driven cancers.

2024-08-03 | GSE273301 | GEO

A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers [scRNA-seq]

2024-08-03 | GSE273300 | GEO

A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers [bulk RNA-seq]

2024-07-30 | GSE273116 | GEO

Sequencing of AsPC-1 cells with CYP3A5 expression modulation

Project description:Purpose: To understand the transcriptome-wide effect of CYP3A5 knockdown or over-expression in AsPC-1 cells

2024-04-17 | GSE149000 | GEO

Expression data from H358

Project description:Tumors that show evidence of epithelial to mesenchymal transition (EMT) have been associated with metastasis, drug resistance, and poor prognosis. EMT may alter the molecular requirements for growth and survival in different contexts, but the underlying mechanisms remain incomplete. Given the heterogeneity along the EMT spectrum between and within tumors it is important to define the requirements for growth and survival in cells with an epithelial or mesenchymal phenotype to maximize therapeutic efficacy. We have established an inducible cell line model in which a tamoxifen regulatable Twist-ER fusion protein is stably expressed in the H358 non-small cell lung cancer cell line. Upon tamoxifen addition, cells undergo EMT and provide a system in which we can compare the growth and survival requirements directly related to EMT, removing confounding factors present when comparing different cell lines. H358 cells stably expressing either GFP or TwistER were treated for 12 days in culture with 100nM 4-hydroxytamoxifen followed by RNA isolation. Three biological replicates of each condition were collected.

2014-01-01 | E-GEOD-52308 | biostudies-arrayexpress

MiRNA microarray of overexpression Ctrl and PRLR AsPC-1 cells.

Project description:The study is to explore differentially expressed miRNAs in AsPC-1 cells overexpressing Ctrl or PRLR.

2022-10-14 | GSE215273 | GEO

Sinorhizobium medicae strain:294

Project description:Sinorhizobium medicae 294 Resequencing

| PRJNA499385 | ENA

Let-7c and miR-294 target identification in mouse ES cells

Project description:let-7c and miR-294 were transfected into Dgcr8 -/- miRNA deficient ES cells and RNA was harvested after 12 hours the goal of this study was to identify direct and indirect targets of the let-7c and miR-294 miRNAs, we chose to harvest RNA early at 12 hours to mimize secondary effects due to ES cell differentiation, prior to performing the array experiment we found that at this time point candidate miRNA targets were maximally downregulated by qPCR

2010-01-01 | GSE18840 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data